Chronic Kidney Disease News and Research

Latest Chronic Kidney Disease News and Research

Routine dipstick urine test may identify individuals with silent kidney disease

A simple and inexpensive urine test routinely done in family doctors' offices may be the key to identifying individuals who are silently undergoing rapid kidney function decline, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

29 Jul 2011

Reprogrammed kidney cells could make transplants and dialysis things of the past

Approximately 60 million people across the globe have chronic kidney disease (CKD), and many will need dialysis or a transplant. Breakthrough research published in the Journal of the American Society Nephrology indicates that patients' own kidney cells can be gathered and reprogrammed.

28 Jul 2011

FDA accepts peginesatide NDA for anemia associated with CKD

Affymax, Inc. and Takeda Global Research & Development Center, Inc., U.S., today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for peginesatide (formerly known as Hematide™) for the treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis.

27 Jul 2011

Safeguard Scientifics reports consolidated net income of $121.8M for second quarter 2011

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced results of operations for the second quarter of 2011.

27 Jul 2011

AMAG enters definitive merger agreement with Allos Therapeutics

AMAG Pharmaceuticals, Inc. and Allos Therapeutics, Inc. today announced that they have entered into a definitive merger agreement under which the companies will combine in an all-stock merger with a total equity value of approximately $686 million.

21 Jul 2011

DaVita's catheter-reduction program lowers CVC rates in hemodialysis patients

DaVita Inc., a leading provider of kidney care services for those diagnosed with end stage renal disease (ESRD) and chronic kidney disease (CKD), today announced that the company has made landmark progress in reducing "Day 90+" patient central venous catheter (CVC) rates, further cementing its position as the industry leader among large dialysis organizations in catheter reductions through the placement of permanent accesses.

14 Jul 2011

Cardiology study looks at sodium and potassium in diet

A new study suggests that in addition to cutting the amount of sodium in their diets to improve heart health, Americans should also increase consumption of a key mineral found in many fruits and vegetables, potassium.

11 Jul 2011

Anti-inflammatory drugs may increase risk of atrial fibrillation

Commonly used painkillers to treat inflammation are linked to an increased risk of irregular heart rhythm, concludes a study published on bmj.com today.

5 Jul 2011

Relypsa initiates dosing in RLY5016 Phase 2b trial for hyperkalemia in diabetic nephropathy and CKD patients

Relypsa, Inc. today announced the start of dosing in a Phase 2b clinical trial of RLY5016 for the treatment of hyperkalemia in patients with diabetic nephropathy and chronic kidney disease (CKD). RLY5016 is a high capacity, non-absorbed, polymer-based potassium binder that is orally administered and has been shown to control serum potassium levels in previous studies.

28 Jun 2011

ChemoCentryx CCX140 Phase II study on type 2 diabetes meets primary endpoint

ChemoCentryx, Inc. today announced that CCX140, the Company's novel, orally active CCR2 antagonist successfully met its primary endpoint of safety and tolerability and demonstrated clinical efficacy in a Phase II study in patients with type 2 diabetes on stable doses of metformin.

28 Jun 2011

FDA directive on anemia drug in kidney disease patients

The U.S. Food and Drug Administration (FDA) has issued new warnings for anemia drugs for patients with kidney disease after studies suggested such drugs could increase stroke risks. The new warnings are the latest to hit the widely used medications since 2007, when the FDA first said they could cause fatal side effects.

27 Jun 2011

FDA recommends conservative dosing guidelines for ESAs to treat anemia in patients with CKD

The U.S. Food and Drug Administration today recommended more conservative dosing guidelines for Erythropoiesis-Stimulating Agents (ESAs) when used to treat anemia in patients with chronic kidney disease (CKD) because of the increased risks of cardiovascular events such as stroke, thrombosis, and death.

27 Jun 2011

New anti-inflammatory drug improves kidney function in patients with type 2 diabetes

A new anti-inflammatory drug used by patients with type 2 diabetes improved their kidney function during a year-long study involving researchers from UT Southwestern Medical Center.

27 Jun 2011

New bardoxolone methyl Phase 2 trial data on kidney disease, diabetes presented at ERA-EDTA 2011

New Phase 2 clinical trial data published online today in The New England Journal of Medicine show that patients with moderate to severe chronic kidney disease and type 2 diabetes receiving bardoxolone methyl for 52 weeks experienced a sustained improvement in kidney function throughout the treatment period, as measured by estimated glomerular filtration rate.

27 Jun 2011

New drug improves kidney function for patients with type 2 diabetes and chronic kidney disease

A new anti-inflammatory drug used by patients with type 2 diabetes improved their kidney function during a year-long study involving researchers from UT Southwestern Medical Center.

24 Jun 2011

InVasc commences INV-144 Phase IIa trial in chronic kidney disease

InVasc Therapeutics, Inc., announced today that it has initiated a Phase IIa, proof of concept (POC), clinical trial with INV-144, a combination drug of losartan with alpha Lipoic Acid (ALA), to slow the progression of chronic kidney disease (CKD) in hypertensive diabetic patients.

24 Jun 2011

Study finds high prevalence of diabetic kidney disease in the U.S.

Over the past 2 decades the prevalence of diabetic kidney disease in the U.S. increased in direct proportion to the prevalence of diabetes itself, according to a study in the June 22/29 issue of JAMA.

22 Jun 2011

Concert to advance CTP-499, C-21191 into Phase 2 trials for diabetic nephropathy and spasticity

Concert Pharmaceuticals, Inc. announced today the advancement of two programs from its DCE Platform. CTP-499 is progressing into Phase 2 clinical trials for diabetic nephropathy and C-21191 has been selected as a lead candidate for spasticity.

20 Jun 2011

Phosphate regulating hormone associated with increased risk of kidney failure and death among CKD patients

A high level of a hormone that regulates phosphate is associated with an increased risk of kidney failure and death among chronic kidney disease (CKD) patients, according to a recent study led by researchers at the University of Miami and funded by the National Institute of Diabetes and Digestive Diseases and Kidney Diseases (NIDDK) at the National Institutes of Health.

16 Jun 2011

High FGF-23 hormone levels linked to increased risk of end-stage renal disease and death

Patients in the early stages of chronic kidney disease who had elevated levels of the endocrine hormone fibroblast growth factor 23 (that regulates phosphorus metabolism) had an associated increased risk of end-stage renal disease and death, according to a study in the June 15 issue of JAMA.

15 Jun 2011

Chronic Kidney Disease News and Research

Latest Chronic Kidney Disease News and Research

Routine dipstick urine test may identify individuals with silent kidney disease

Reprogrammed kidney cells could make transplants and dialysis things of the past

FDA accepts peginesatide NDA for anemia associated with CKD

Safeguard Scientifics reports consolidated net income of $121.8M for second quarter 2011

AMAG enters definitive merger agreement with Allos Therapeutics

DaVita's catheter-reduction program lowers CVC rates in hemodialysis patients

Cardiology study looks at sodium and potassium in diet

Anti-inflammatory drugs may increase risk of atrial fibrillation

Relypsa initiates dosing in RLY5016 Phase 2b trial for hyperkalemia in diabetic nephropathy and CKD patients

ChemoCentryx CCX140 Phase II study on type 2 diabetes meets primary endpoint

FDA directive on anemia drug in kidney disease patients

FDA recommends conservative dosing guidelines for ESAs to treat anemia in patients with CKD

New anti-inflammatory drug improves kidney function in patients with type 2 diabetes

New bardoxolone methyl Phase 2 trial data on kidney disease, diabetes presented at ERA-EDTA 2011

New drug improves kidney function for patients with type 2 diabetes and chronic kidney disease

InVasc commences INV-144 Phase IIa trial in chronic kidney disease

Study finds high prevalence of diabetic kidney disease in the U.S.

Concert to advance CTP-499, C-21191 into Phase 2 trials for diabetic nephropathy and spasticity

Phosphate regulating hormone associated with increased risk of kidney failure and death among CKD patients

High FGF-23 hormone levels linked to increased risk of end-stage renal disease and death

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Chronic Kidney Disease News and Research

Latest Chronic Kidney Disease News and Research

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in